| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.74 | -0.03 (-0.63%) | 4.19 - 6.95 | 773.5 thousand (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 4.79 |
|---|---|
| Previous Close | 4.77 |
| Day's Range | 4.67 - 4.80 |
| Market Cap | 871.2M |
| Avg Volume (10 Day) | 1.7M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.98 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting
Business Wire - Wednesday 05/15/2013 4:02 PM ET
Exelixis Announces Webcasts of Upcoming Investor Conference Presentations
Business Wire - Wednesday 05/08/2013 5:42 PM ET
Exelixis Announces First Quarter 2013 Financial Results
Business Wire - Tuesday 05/07/2013 4:15 PM ET
Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting
Business Wire - Tuesday 05/07/2013 4:13 PM ET
| EXEL | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -85.82% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 1.30 | |
| LT Debt/Equity | 1.25 | |
| Earnings Yield | -- | |
| Price/Sales | 22.57 |
| Company | Last | Change |
|---|---|---|
| Halozyme Therapeutics Inc | 7.42 | -0.40% |
| Clovis Oncology Inc | 34.60 | +3.28% |
| InterMune Inc | 9.58 | -3.82% |
| Celldex Therapeutics Inc | 12.41 | +0.89% |
| Achillion Pharmaceuticals Inc | 7.58 | -0.79% |
Data is delayed by at least 15 min.